Fox S H, Brotchie J M
Movement Disorder Clinic, Edmond J Safra Program in Parkinson Disease, Krembil Research Institute, Toronto Western Hospital, 399, Bathurst St, Toronto, ON, M5T 2S8, Canada.
Krembil Institute, Toronto Western Hospital, 60 Leonard Ave, Toronto, ON, M5T 0S8, Canada; Atuka Ltd, Suite 5600, First Canadian Place, 100 King Street West, Toronto, ON, M5X 1C9, Canada.
Neuropharmacology. 2022 May 1;208:108998. doi: 10.1016/j.neuropharm.2022.108998. Epub 2022 Feb 10.
Parkinson's disease (PD) is a common neurodegenerative disorder. Age is the biggest risk factor, with the prevalence rising from 1% in 45-54 year age group to 2-4% in 85 year or older. Population increases have led some to predict that we are facing a 'PD Pandemic' with the prevalence doubling in the next two decades. There is thus an urgent need for effective therapies to reduce disease burden. In this Special Issue of Neuropharmacology invited authors have reviewed current and emerging targets for pharmacological therapy for PD covering the areas of disease modification, i.e. addressing the underlying disease processes, through to symptomatic therapies, whether for motor or non-motor symptoms of the disease. The articles are from leaders in the field and represent preclinical and clinical stages of therapeutic development. The Special Issue highlights that there is ongoing significant activity across all these potential indications and a vast array of targets have been identified and validated to different extents. PD is, and will remain for the foreseeable future, for the neuropharmacologist a significant area of research, in both the preclinical and clinical space.
帕金森病（PD）是一种常见的神经退行性疾病。年龄是最大的风险因素，患病率从45 - 54岁年龄组的1%上升至85岁及以上人群的2 - 4%。人口增长使得一些人预测，我们正面临一场“帕金森病大流行”，预计在未来二十年内患病率将翻倍。因此，迫切需要有效的治疗方法来减轻疾病负担。在本期《神经药理学》特刊中，受邀作者回顾了帕金森病药物治疗的当前和新兴靶点，涵盖了从疾病修饰（即针对潜在疾病进程）到对症治疗（无论是针对该疾病的运动症状还是非运动症状）等领域。这些文章均出自该领域的领军人物，代表了治疗研发的临床前和临床阶段。该特刊强调，在所有这些潜在适应症方面都有持续的重要研究活动，并且已经确定并在不同程度上验证了大量靶点。在可预见的未来，帕金森病对于神经药理学家而言，在临床前和临床领域都将是一个重要的研究领域。
